bioRxiv Science⌕ Search

Biology subjects

Tweel, B.

Publications and source records attributed to Tweel, B..

3 recordsLinked to original sources

A transcriptional continuum links viral burden and host-cell biology in human lymphoid tissue

Human immunodeficiency virus (HIV-1) persistence in lymphoid tissue remains a major barrier to cure, yet infected cells are commonly represented using discrete categories that may obscure biologically meaningful heterogeneity. Using an ex vivo human tonsil explant model and single-cell RNA sequencing of more than 42,000 T cells, we show that HIV transcription spans a structured continuum and that viral transcriptional burden functions as an organizing axis of host-cell biology. Across the continuum, increasing HIV transcription is associated with coordinated remodeling of immune, inflammatory, metabolic, and redox-associated programs. Lower transcriptional tiers were enriched for innate sensing and inflammasome-associated responses, whereas higher tiers exhibited activation of oxidative phosphorylation and redox-buffering pathways. Antiretroviral therapy preferentially depleted highly transcriptionally active populations while preserving lower and intermediate tiers, resulting in compression rather than elimination of the continuum. Together, these findings provide a quantitative framework for interpreting HIV transcriptional heterogeneity within human lymphoid tissue and suggest that persistent viral activity reflects a spectrum of host-virus states rather than a single infected-cell population. By linking viral transcriptional burden to distinct host-cell programs, this framework may inform future strategies to reduce HIV persistence and its associated inflammatory consequences.

immunology↗

Immunological landscape of human lymph nodes during ex vivo measles virus infection

In humans, lymph nodes are the primary site of measles virus (MeV) replication. To understand the immunological events that occur at this site, we infected human lymphoid tissue explants using a pathogenic strain of MeV that expresses GFP. We found that MeV infected between 5-15% of cells across donors. Using single cell RNA-Seq (scRNA-Seq) and flow cytometry, we found that while most of the 29 cell populations identified in the lymphoid culture were susceptible to MeV, there was a broad preferential infection of B cells and reduced infection of T cells. Further subsetting of T cells revealed that this reduction may be driven by the decreased infection of naive T cells. Transcriptional changes in infected B cells were dominated by an interferon stimulated gene (ISG) signature. To determine which of these ISGs were most substantial, we evaluated the proteome of MeV-infected Raji cells by mass spectrometry. We found that IFIT1, IFIT2, IFIT3, ISG15, CXCL10, MX2, and XAF1 proteins were the most highly induced, and positively correlated with their expression in the transcriptome. These data provide insight into the immunological events that occur in lymph nodes during infection and may lead to the development of therapeutic interventions.

immunology↗

P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines IL-10 and IL-1β in a human tonsil explant model

HIV-1 causes a persistent infection of the immune system that is associated with chronic comorbidities. The mechanisms that underlie this inflammation are poorly understood. Emerging literature has implicated pro-inflammatory purinergic receptors and downstream signaling mediators in HIV-1 infection. This study probed whether inhibitors of purinergic receptors would reduce HIV-1 infection and HIV-1 stimulated inflammation. A human ex vivo human tonsil histo-culture infection model was developed to support HIV-1 productive infection and stimulated inflammatory cytokine interleukin-1 beta (IL-1{beta}) and immunosuppressive cytokine, interleukin-10 (IL-10). This study tests whether inhibitors of purinergic receptors would reduce HIV-1 infection and HIV-1 stimulated inflammation. The purinergic P2X1 receptor antagonist, NF449, the purinergic P2X7 receptor antagonists, A438079, and azidothymidine (AZT) were tested in HIV-1 infected human tonsil explants to compare inhibition of HIV-1 infection and HIV-stimulated inflammatory cytokine production. All drugs limited HIV-1 productive infection but P2X-selective antagonists (NF449, and A438079) significantly lowered HIV-stimulated IL-10 and IL-1{beta}. We further observed that P2X1- and P2X7-selective antagonists can act differentially as inhibitors of both HIV-1 infection and HIV-1-stimulated inflammation. Our findings highlight the differential effects of HIV-1 on inflammation in peripheral blood as compared to lymphoid tissue. For the first time, we demonstrate that P2X-selective antagonists act differentially as inhibitors of both HIV-1 infection and HIV-1-stimulated inflammation. Drugs that block these pathways can have independent inhibitory activities against HIV-1 infection and HIV-induced inflammation.\n\nImportancePatients who are chronically infected with HIV-1 experience sequelae related to chronic inflammation. The mechanisms of this inflammation have not been elucidated. Here we describe a class of drugs that target the P2X pro-inflammatory signaling receptors in a human tonsil explant model. This model highlights differences in HIV-1 stimulation of lymphoid tissue inflammation and peripheral blood. These drugs serve to both block HIV-1 infection and production of IL-10 and IL-1{beta} in lymphoid tissue suggesting a novel approach to HIV-1 therapeutics in which both HIV-1 replication and inflammatory signaling are simultaneously targeted.

immunology↗